Keywords: Bristol-Myers Squibb, Third-quarter 2010 financial results
Bristol-Myers Squibb posts flat 3rd-qtr 2010 sales, but EPS beats expectations
Article | 27 October 2010
US drug major Bristol-Myers Squibb (NYSE: BMY) posted third quarter 2010 net sales of $4.80 billion, just marginally higher than the $4.79 billion ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
